Robert E Goldsby1, Kayla L Stratton2, Shannon Raber1, Arthur Ablin1, Louise C Strong3, Kevin Oeffinger4, Charles A Sklar4, Gregory T Armstrong5, Leslie L Robison5, Smita Bhatia6, Wendy M Leisenring2. 1. Pediatric Hematology/Oncology, University of California-San Francisco Benioff Children's Hospital, San Francisco, California. 2. Clinical Biostatistics and Cancer Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. Division of Pediatrics, MD Anderson Cancer Center, Houston, Texas. 4. Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York. 5. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Pediatric Hematology/Oncology, Children's Hospital of Alabama, Birmingham, Alabama.
Abstract
BACKGROUND: Children with Down syndrome (DS) are at increased risk of developing acute leukemia and are more prone to acute toxicities. We studied the incidence and severity of chronic health conditions among survivors of childhood leukemia with DS compared with those without DS. METHODS: Chronic health conditions reported by questionnaire were compared between 154 pediatric leukemia survivors with DS and 581 without DS, matched by leukemia, age at diagnosis, race/ethnicity, sex, radiation location and chemotherapy exposure using Cox models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Subjects were selected from 7139 5-year survivors of leukemia in the Childhood Cancer Survivor Study. RESULTS: Risk of at least 1 late onset chronic health condition (grade 1-5) was similar in the DS population compared with the non-DS group (HR, 1.1; 95% CI, 0.7-1.5). Serious chronic health conditions (grade 3-5) were more common in DS survivors (HR, 1.7; 95% CI, 1.1-2.6), as were ≥ 3 chronic health conditions (grades 1-5) (HR, 1.7; 95% CI, 1.2-2.4). The 25-year cumulative incidence of any condition (grades 1-5) was 83% for DS survivors and 69% for non-DS survivors. CONCLUSION: Leukemia survivors with DS have therapy-related chronic health conditions comparable to those of similarly treated survivors without DS, with a few notable exceptions: 1) an increased risk of cataracts, hearing loss, and thyroid dysfunction compared with survivors without DS (though these are known risks in the DS population), 2) decreased risk of second cancers, and 3) increased risk of severe or multiple conditions. Practitioners should be aware of these risks during and after therapy. Cancer 2018;124:617-25.
BACKGROUND:Children with Down syndrome (DS) are at increased risk of developing acute leukemia and are more prone to acute toxicities. We studied the incidence and severity of chronic health conditions among survivors of childhood leukemia with DS compared with those without DS. METHODS: Chronic health conditions reported by questionnaire were compared between 154 pediatric leukemia survivors with DS and 581 without DS, matched by leukemia, age at diagnosis, race/ethnicity, sex, radiation location and chemotherapy exposure using Cox models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Subjects were selected from 7139 5-year survivors of leukemia in the Childhood Cancer Survivor Study. RESULTS: Risk of at least 1 late onset chronic health condition (grade 1-5) was similar in the DS population compared with the non-DS group (HR, 1.1; 95% CI, 0.7-1.5). Serious chronic health conditions (grade 3-5) were more common in DS survivors (HR, 1.7; 95% CI, 1.1-2.6), as were ≥ 3 chronic health conditions (grades 1-5) (HR, 1.7; 95% CI, 1.2-2.4). The 25-year cumulative incidence of any condition (grades 1-5) was 83% for DS survivors and 69% for non-DS survivors. CONCLUSION:Leukemia survivors with DS have therapy-related chronic health conditions comparable to those of similarly treated survivors without DS, with a few notable exceptions: 1) an increased risk of cataracts, hearing loss, and thyroid dysfunction compared with survivors without DS (though these are known risks in the DS population), 2) decreased risk of second cancers, and 3) increased risk of severe or multiple conditions. Practitioners should be aware of these risks during and after therapy. Cancer 2018;124:617-25.
Authors: Gregory T Armstrong; Toana Kawashima; Wendy Leisenring; Kayla Stratton; Marilyn Stovall; Melissa M Hudson; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: M Dördelmann; M Schrappe; A Reiter; M Zimmermann; N Graf; G Schott; F Lampert; J Harbott; C Niemeyer; J Ritter; W Dörffel; G Nessler; J Kühl; H Riehm Journal: Leukemia Date: 1998-05 Impact factor: 11.528
Authors: James A Whitlock; Harland N Sather; Paul Gaynon; Leslie L Robison; Robert J Wells; Michael Trigg; Nyla A Heerema; Smita Bhatia Journal: Blood Date: 2005-08-18 Impact factor: 22.113
Authors: Maureen M O'Brien; Jeffrey W Taub; Myron N Chang; Gita V Massey; Kimo C Stine; Susana C Raimondi; David Becton; Yaddanapudi Ravindranath; Gary V Dahl Journal: J Clin Oncol Date: 2008-01-20 Impact factor: 44.544
Authors: Y Ravindranath; E Abella; J P Krischer; J Wiley; S Inoue; M Harris; A Chauvenet; C S Alvarado; R Dubowy; A K Ritchey Journal: Blood Date: 1992-11-01 Impact factor: 22.113
Authors: Kirsten K Ness; Kevin R Krull; Kendra E Jones; Daniel A Mulrooney; Gregory T Armstrong; Daniel M Green; Wassim Chemaitilly; Webb A Smith; Carmen L Wilson; Charles A Sklar; Kyla Shelton; Deo Kumar Srivastava; Sabeen Ali; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2013-11-18 Impact factor: 44.544
Authors: Brianna R Murphy; Michael Roth; E Anders Kolb; Todd Alonzo; Robert Gerbing; Robert J Wells Journal: Pediatr Blood Cancer Date: 2019-03-25 Impact factor: 3.167
Authors: Nina Streefkerk; Wim J E Tissing; Margriet van der Heiden-van der Loo; Elizabeth A M Lieke Feijen; Eline van Dulmen-den Broeder; Jacqueline J Loonen; Helena J H van der Pal; Cécile M Ronckers; Hanneke M van Santen; Marleen H van den Berg; Renée L Mulder; Joke C Korevaar; Leontine C M Kremer Journal: J Cancer Surviv Date: 2020-05-03 Impact factor: 4.442
Authors: Elizabeth A M Feijen; Wendy M Leisenring; Kayla L Stratton; Kirsten K Ness; Helena J H van der Pal; Elvira C van Dalen; Gregory T Armstrong; Gregory J Aune; Daniel M Green; Melissa M Hudson; Jacqueline Loonen; Kevin C Oeffinger; Leslie L Robison; Yutaka Yasui; Leontien C M Kremer; Eric J Chow Journal: JAMA Oncol Date: 2019-06-01 Impact factor: 31.777
Authors: James A Hendrix; Angelika Amon; Leonard Abbeduto; Stamatis Agiovlasitis; Tarek Alsaied; Heather A Anderson; Lisa J Bain; Nicole Baumer; Anita Bhattacharyya; Dusan Bogunovic; Kelly N Botteron; George Capone; Priya Chandan; Isabelle Chase; Brian Chicoine; Cécile Cieuta-Walti; Lara R DeRuisseau; Sophie Durand; Anna Esbensen; Juan Fortea; Sandra Giménez; Ann-Charlotte Granholm; Laura J Hahn; Elizabeth Head; Hampus Hillerstrom; Lisa M Jacola; Matthew P Janicki; Joan M Jasien; Angela R Kamer; Raymond D Kent; Bernard Khor; Jeanne B Lawrence; Catherine Lemonnier; Amy Feldman Lewanda; William Mobley; Paul E Moore; Linda Pollak Nelson; Nicolas M Oreskovic; Ricardo S Osorio; David Patterson; Sonja A Rasmussen; Roger H Reeves; Nancy Roizen; Stephanie Santoro; Stephanie L Sherman; Nasreen Talib; Ignacio E Tapia; Kyle M Walsh; Steven F Warren; A Nicole White; Guang William Wong; John S Yi Journal: Transl Sci Rare Dis Date: 2021-04-15